Navigation Links
Phase 2b Study of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Shows Undetectable Virus in HCV Genotype-1 Patients 12 Weeks After Treatment Ended (SVR12)
Date:4/19/2012

#8211; 7:30 a.m. EDTImpact of early response
definitions on duration and
outcome of treatment with
BI 201335 plus pegylated-
interferon plus ribavirin

M. Sulkowski

Poster# 1209

 

Date: Sat, April 21

Time: 12:30 – 1:30 p.m.
CEST/ 6:30 – 7:30 a.m. EDTPreclinical characterization of
the hepatitis C virus NS5B
polymerase non-nucleoside
inhibitor BI 207127

P. Beaulieu

Poster# 822

 

Date: Fri, April 20

Time: 12:30 – 2:00 p.m.
CEST/ 6:30 – 8:00 a.m. EDT 

About Hepatitis C Virus (HCV)HCV is an infectious disease of the liver and is a leading cause of chronic liver disease, transplant and failure that affects as many as 170 million people globally, with three to four million new infections occurring each year. In the United States, an estimated 4.1 million Americans have been infected with HCV, of which approximately 3.2 million have chronic HCV infection. The majority – about 75 to 85 percent – of HCV cases will develop into chronic infection. It is estimated 20 percent of patients with chronic HCV will develop cirrhosis within 20 years of infection. The mortality rate after cirrhosis has developed is 2 – 5 percent per year. Chronic HCV infection is the cause of an estimated 8,000 to 10,000 deaths annually in the United States.

About Boehringer Ingelheim in Hepatitis C Virus (HCV)Boehringer Ingelheim has a long-standing commitment to virology, including developing innovative therapies for HCV and HIV/AIDS. Through pioneering science, BI strives to achieve a far reaching and inclusive HCV cure that may ease the impact of the disease. In partnership with the scientific community, our clinical trial program, HCVerso™, is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat.

BI 201335, an investigational
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CrystalGenomics Announces Positive Results from Phase 2b Osteoarthritis Study of CG100649
2. Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer
3. Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain
4. QRxPharma Successfully Completes Phase 1 Studies for MoxDuo® CR
5. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
6. UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
7. Bionovos Independent Data Safety Monitoring Board Recommends Continuation of Phase 3 Study for Menerba™
8. Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
9. iBio Announces Successful Completion of H1N1 Influenza Vaccine Phase 1 Clinical Trial
10. Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
11. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  In recognition of ... commitment to the global bleeding disorders community, CSL ... million international units (IUs) of protein therapies to the ... not-for- profit organization which has worked to improve the ... disorders. The donation supports the WFH,s Global Alliance for ...
(Date:2/27/2015)... 27, 2015  Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, announced today that ... Officer, will present live at VirtualInvestorConferences.com on March ... join us for this Company update," said Mr. ... commercial launch of the exVive3D Liver, Bioprinted Human ...
(Date:2/27/2015)...  Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... acquired Bionik Laboratories, Inc., a Toronto ... qualified accredited investors of units consisting of its common ... $6.2 million. Shares of the Company,s common stock will ... the symbol "DWTPD" until FINRA,s approval of the ticker ...
Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... data presented at the 60th Annual Meeting of the ... American Academy of Neurology (AAN) in Chicago, SMYRNA, ... pooled analyses of Phase II and III double-blind, randomized,placebo-controlled clinical ... data, which were presented at,the 60th Annual Meeting of the ...
... 16 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... independent data safety monitoring board (DSMB) has,recommended continuation ... to,determine whether a brief intravenous infusion of Viprinex(TM) ... functional outcome at 3,months. This is the fifth ...
Cached Medicine Technology:Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain 2Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain 3Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod) 2
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
(Date:2/28/2015)... Flagstaff, AZ (PRWEB) February 28, 2015 ... drug and alcohol treatment center , and current student ... State University, has implemented a weekly forum in psychoeducation ... high school in Flagstaff, AZ as part of her ... a big need for support and counseling at the ...
(Date:2/28/2015)... ON (PRWEB) February 28, 2015 The ... Art of Facial Surgery was recently featured in the ... of the magazine, Dr. David Ellis was featured in ... discussed the various cosmetic enhancements that Kim Cattrall has ... , “Her forehead is smooth without horizontal lines ...
(Date:2/28/2015)... February 28, 2015 Plugin creators from ... Volume 2. A fully customizable transition pack ... Volume 2 gives users total control over 30 transition ... CEO of Pixel Film Studios. “TransFold Volume 2 gives ... , TransFold Volume 2 from Pixel Film Studios brings ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 ... supported and showcased emerging brand at Houston Texas ... in Las Vegas sending its executive delegates headed ... of Business Development and Training Randolph Clarito. , ... (IFA), was held last February 4-7 and featured ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3
... an expanding waist line, weight gain and a tendency to ... a study published today in the journal Nature Genetics. ... significantly more common in those with Indian Asian than European ... Foundation, could lead to better ways of treating obesity. , ...
... hospitalizing young children for influenza creates a significant economic ... preventive flu shots for children and the people with ... by Cincinnati Childrens Hospital Medical Center and presented May ... Honolulu, Hawaii. , After analyzing data in three U.S. ...
... reflux, urinary incontinence ,slow down, seniors, studies say ... studies show that anticholinergics, a commonly prescribed group of ... their daily physical activities. , The two reports from ... findings released a few weeks ago that anticholinergic drugs ...
... no health insurance don,t see a doctor all year ... children share at least one frightening fact: If they are ... health care... period. , New research from the University ... children in families earning between $38,000 and $77,000 annually who ...
... and $77,000 a year are just as likely to ... poorer families. More than 40 percent of children in ... no physicians and have no prescriptions all year, according ... Center. , Theres an assumption that children in families ...
... Australian researchers have unveiled a new immunotherapy technique ... to AIDS. Details of the simple, cost-effective ... journal PLoS Pathogens. , There is an overwhelming ... therapies are expensive, impractical, and often highly toxic. ...
Cached Medicine News:Health News:Gene sequence that can make half of us fatter is discovered 2Health News:Young children hospitalized for flu associated with higher costs and higher risk illness 2Health News:Common Medications Could Cause Physical Impairment in the Elderly 2Health News:Middle Class Uninsured Kids' Health Risk Almost as High as Poor Children's 2Health News:Uninsured kids in middle class have same unmet needs as poor 2Health News:Uninsured kids in middle class have same unmet needs as poor 3
... The Gemini Family of infusion ... with a collective series of ... product line offers a wide ... IV sets, each featuring the ...
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... itself to over 2,000 medical clinics nation ... user in mind, ChartingPlus relies heavily on ... features to improve documentation quality and increase ... Our medical content is specific to your ...
Transfer your exams to AltaPoint with our EMR Exam Word Lists. Document systems as normal and annotate exceptions to the systems in the exam. AltaPoint EMR is configured to allow a specialty to cust...
Medicine Products: